Zacks Investment Research upgraded shares of Pluristem Therapeutics (NASDAQ:PSTI) from a sell rating to a hold rating in a report issued on Wednesday, Zacks.com reports.

According to Zacks, “PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. “

Separately, Maxim Group reissued a buy rating and set a $3.00 price target on shares of Pluristem Therapeutics in a report on Wednesday, April 24th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $3.19.

Shares of NASDAQ PSTI opened at $0.67 on Wednesday. Pluristem Therapeutics has a 1 year low of $0.50 and a 1 year high of $1.52. The firm has a market cap of $97.36 million, a P/E ratio of -2.68 and a beta of 1.13.

In other news, CEO Yaky Yanay purchased 71,429 shares of the stock in a transaction that occurred on Monday, April 8th. The shares were purchased at an average cost of $0.70 per share, with a total value of $50,000.30. Following the completion of the acquisition, the chief executive officer now owns 4,253,045 shares of the company’s stock, valued at approximately $2,977,131.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 6.70% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. ETF Managers Group LLC raised its position in Pluristem Therapeutics by 49.6% during the fourth quarter. ETF Managers Group LLC now owns 250,848 shares of the biotechnology company’s stock worth $192,000 after acquiring an additional 83,207 shares during the period. Virtu Financial LLC raised its position in Pluristem Therapeutics by 266.1% during the first quarter. Virtu Financial LLC now owns 85,104 shares of the biotechnology company’s stock worth $83,000 after acquiring an additional 61,858 shares during the period. Nikko Asset Management Americas Inc. acquired a new position in Pluristem Therapeutics during the first quarter worth $900,000. Renaissance Technologies LLC raised its position in Pluristem Therapeutics by 5.8% during the third quarter. Renaissance Technologies LLC now owns 1,331,100 shares of the biotechnology company’s stock worth $1,730,000 after acquiring an additional 72,600 shares during the period. Finally, Jane Street Group LLC raised its position in Pluristem Therapeutics by 337.4% during the third quarter. Jane Street Group LLC now owns 94,023 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 72,526 shares during the period. 5.93% of the stock is currently owned by hedge funds and other institutional investors.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Recommended Story: Convertible Shares

Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.